D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson’s and Alzheimer’s diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and chronic pancreatitis indications; NLY02, an oral small molecule for PD and AD indications; and P4M01 for anti-microbial peptide indications. In addition, it develops PMI07, PMI05, and PMI06 for solid tumor imaging biomarker indications; and PMI04 for neuroinflammation indications. The company was founded in 2014 and is based in Seongnam-si, South Korea.
Metrics to compare | 347850 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship347850PeersSector | |
|---|---|---|---|---|
P/E Ratio | −118.4x | −16.0x | −0.6x | |
PEG Ratio | −4.91 | −0.14 | 0.00 | |
Price/Book | 54.6x | 4.2x | 2.6x | |
Price / LTM Sales | 491.9x | 21.0x | 3.4x | |
Upside (Analyst Target) | - | 16.0% | 44.9% | |
Fair Value Upside | Unlock | −6.5% | 6.7% | Unlock |